Thrombosis in continuous-flow left ventricular assist devices: Pathophysiology, prevention, and pharmacologic management

Pharmacotherapy

Volumn 35, Issue 1, 2015, Pages 79-98

  Jennings, Douglas L ^a,b   Weeks, Phillip A ^c  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

^c EAST TEXAS MEDICAL CENTER   (United States)

Author keywords

Direct thrombin inhibitor; Glycoprotein IIb IIIa inhibitor; Left ventricular assist device; Thrombolytic; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ARGATROBAN; CLOPIDOGREL; DOBUTAMINE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIGH MOLECULAR WEIGHT KININOGEN; HIRUDIN; HIRULOG; MILRINONE; PRASUGREL; TENECTEPLASE; THROMBIN INHIBITOR; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR;

ANTICOAGULANT THERAPY; BIOCOMPATIBILITY; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; DEVICE INFECTION; DEVICE THROMBOSIS; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HAND TRANSPLANTATION; HEART FAILURE; HEMATOMA; HEMATOTHORAX; HEMATURIA; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL ADMISSION; HUMAN; HYPERCOAGULABILITY; INFECTION; INTERNATIONAL NORMALIZED RATIO; MEDICAL DEVICE COMPLICATION; MELENA; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PEPTIC ULCER BLEEDING; PERICARDIAL EFFUSION; RECURRENT DISEASE; REVIEW; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BLOOD; CORONARY ARTERY BLOOD FLOW; DRUG EFFECTS; HEART ASSIST DEVICE; HEART VENTRICLE; PHYSIOLOGY;

BLOOD COAGULATION; CLINICAL TRIALS AS TOPIC; CORONARY CIRCULATION; FIBRINOLYTIC AGENTS; HEART VENTRICLES; HEART-ASSIST DEVICES; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOSIS;

EID: 84924880506     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1501     Document Type: Review

References (55)

1. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report-2012. J Heart Lung Transplant 2012;31:1052-64.
2. Kirklin JK, Naftel DC, Kormos RL, et al. Fifth INTERMACS annual report: risk factor analysis from more than 6, 000 mechanical circulatory support patients. J Heart Lung Transplant 2013;32:141-56.
3. Starling RC, Moazami N, Silvestry SC, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 2014;370:33-40.
4. Uriel N, Han J, Morrison KA, et al. Device thrombosis in HeartMate II continuous-flow left ventricular assist devices: a multifactorial phenomenon. J Heart Lung Transplant 2014 Jan;33:51-9.
5. Taghavi S, Ward C, Jayarajan SN, Gaughan J, Wilson LM, Mangi AA. Surgical technique influences HeartMate II left ventricular assist device thrombosis. Ann Thorac Surg 2013;96:1259-65.
6. Frazier OH, Delgadon RM, Kar B, et al. First clinical use of the redesigned HeartMate II left ventricular assist system in the United States. Tex Heart Inst J 2004;31:157-9.
7. John R, Panch S, Hrabe J, et al. Activation of endothelial and coagulation systems in left ventricular assist device recipients. Ann Thorac Surg 2009;88:1171-9.
8. Slaughter MS, Sobieski MA, Gallagher C, Graham J, Brandise J, Stein R. Fibrinolytic activation during long-term support with the HeartMate II left ventricular assist device. ASAIO J 2008;54:115-9.
9. Thor A, Rasmusson L, Wennerberg A, et al. The role of whole blood in thrombin generation in contact with various titanium surfaces. Biomaterials 2007;28:966-74.
10. Weber N, Wendel HP, Ziemer G. Hemocompatibility of heparin coated surfaces and the role of selective plasma protein adsorption. Biomaterials 2002;23:429-39.
11. Nielsen VG, Kirklin JK, Holman WL, et al. Mechanical circulatory device thrombosis: a new paradigm linking hypercoagulation and hypofibrinolysis. ASAIO J 2008;54:351-8.
12. Amir O, Bracey AW, Smart FW, et al. A successful anticoagulation protocol for the first HeartMate II implantation in the United States. Tex Heart Inst J 2005;32:399-401.
13. Boyle AJ, Russell SD, Teuteberg JJ, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant 2009;28:881-7.
14. Slaughter MS, Pagani FD, Rogers JG, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant 2010;29:S1-39.
15. Sundareswaran KS, Farrar DJ. No difference in pump thrombosis in Heartmate II patients with gelatin sealed and unsealed vascular grafts [abstract]. J Heart Lung Transplant 2014;33:S131.
16. Kirklin JK, Naftel DC, Kormos RL, et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant 2014;33:12-22.
17. Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant 2013;32:157-87.
18. Houël R, Mazoyer E, Boval B, et al. Platelet activation and aggregation profile in prolonged ventricular support. J Thorac Cardiovasc Surg 2004;128:197-202.
19. Bonaros N, Mueller MH, Salat A, et al. Extensive coagulation monitoring in patients after implantation of the micromed debakey continuous flow axial pump. ASAIO J 2004;50:424-31.
20. Ensor CR, Paciullo CA, Cahoon WD, Nolan PE. Pharmacotherapy for mechanical circulatory support: a comprehensive review. Ann Pharmacother 2011;45:60-77.
21. Slaughter MS, Sobieski MA 2nd, Graham JD, et al. Platelet activation in heart failure patients supported by the HeartMate II ventricular assist device. Int J Artif Organs 2011;34:461-8.
22. Litzler PY, Smail H, Barbay V, et al. Is anti-platelet therapy needed in continuous flow left ventricular assist device patients? A single-centre experience. Eur J Cardiothorac Surg 2014;45:55-9.
23. Birschmann I, Dittrich M, Eller T, et al. Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices. J Heart Lung Transplant 2014;33:80-7.
24. Slaughter MS, Pagani FD, McGee EC, et al. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant 2013;32:675-83.
25. Najjar SS, Slaughter MS, Pagani FD, et al. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. J Heart Lung Transplant 2014;33:23-34.
26. Ravichandran AK, Parker J, Novak E, et al. Hemolysis in left ventricular assist device: a retrospective analysis of outcomes. J Heart Lung Transplant 2014;33:44-50.
27. Cowger JA, Romano MA, Shah P, et al. Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant. J Heart Lung Transplant 2014;33:35-43.
28. Mishkin JD, Enriquez JR, Meyer DM, et al. Utilization of cardiac computed tomography angiography for the diagnosis of left ventricular assist device thrombosis. Circ Heart Fail 2012;1:e27-9.
29. Uriel N, Morrison KA, Garan AR, et al. Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp study. J Am Coll Cardiol 2012;30:1764-75.
30. Rothenburger M, Wilhelm MJ, Hamme D. Treatment of thrombus formation associated with the MicroMed DeBakey VAD using recombinant tissue plasminogen activator. Circulation 2002;106(suppl I):189-92.
31. Delgado R 3rd, Frazier OH, Myers TJ, et al. Direct thrombolytic therapy for intraventricular thrombosis in patients with the Jarvik 2000 left ventricular assist device. J Heart Lung Transplant 2005;24:231-3.
32. Goldstein DJ, John R, Salerno C, et al. Algorithm for the diagnosis and management of suspected pump thrombus. J Heart Lung Transplant 2013;32:667-70.
33. Blais DM, Sun B, Vesco P, Louis LB, Sai-Sudhakar C, Firstenberg MS. Profound thrombocytopenia with glycoprotein IIb/IIIa inhibitors plus heparin for pump thrombus. J Heart Lung Transplant 2008;27:1361-2.
34. Al-Quthami AH, Jumean M, Kociol R, et al. Eptifibatide for the treatment of HeartMate II left ventricular assist device thrombosis. Circ Heart Fail 2012;5:e68-70.
35. Jennings DL, Cabrera R, Wang D, Tita C. Successful treatment of a continuous flow left-ventricular assist device thrombosis with eptifibatide. ASAIO J 2012;58:633-5.
36. Thenappan T, Anderson AS, Jeevanadham V, Rich JD, Shah AP. Treatment of left ventricular assist device thrombosis with extended catheter-directed intraventricular thrombolytic therapy. Circ Heart Fail 2013;6:e27-9.
37. Bellumkonda L, Subrahmanyan L, Jacoby D, Bonde P. Left ventricular assist device pump thrombosis: is there a role for glycoprotein IIb/IIIa inhibitors? ASAIO J 2014;60:134-6.
38. Tellor BR, Smith JR, Prasad SM, Joseph SM, Silvestry SC. The use of eptifibatide for suspected pump thrombus or thrombosis in patients with left ventricular assist devices. J Heart Lung Transplant 2014;33:94-101.
39. Paluszkiewicz L, Gürsoy D, Spiliopoulos S, et al. HeartMate II ventricular assist device thrombosis-an echocardiographic approach to diagnosis: can Doppler evaluation of flow be useful? J Am Soc Echocardiogr 2011;24:e1-4.
40. Tang GH, Kim MC, Pinney SP, Anyanwu AC. Failed repeated thrombolysis requiring left ventricular assist device pump exchange. Catheter Cardiovasc Interv 2013;81:1072-4.
41. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clotincorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994;72:381-6.
42. Nielsen VG, Steenwyk BL, Gurley WQ, Pereira SJ, Lell WA, Kirklin JK. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro. J Heart Lung Transplant 2006;25:653-63.
43. Meyer AL, Kuehn C, Weidemann J, et al. Thrombus formation in a HeartMate II left ventricular assist device. J Thorac Cardiovasc Surg 2008;135:203-4.
44. Badiye A, Hernandez GA, Chaparro S. Argatroban as novel therapy for suspected thrombosis in patients with continuous flow left ventricle assist device and hemolysis. ASAIO J 2014;60(3):361-5.
45. Muthiah K, Macdonald PS, Kotlyar E, et al. Thrombolysis for suspected intrapump thrombosis in patients with continuous flow centrifugal left ventricular assist device. Artif Organs 2013;37:313-22.
46. Aissaoui N, Borgermann J, Gummert J, et al. HeartWare continuous-flow ventricular assist device thrombosis: the Bad Oeynhausen experience. J Thorac Cardiovasc Surg 2012;143:e37-9.
47. Kiernan MS, Pham DT, DeNofrio D, et al. Management of HeartWare left ventricular assist device thrombosis using intracavitary thombolytics. J Thorac Cardiovasc Surg 2011;142:712-4.
48. Kamouh A, John R, Eckman P. Successful treatment of early thrombosis of heartware left ventricular assist device with thrombolytics. Ann Thorac Surg 2012;94:281-3.
49. Santise G, Sciacca S, Baglini R, et al. Can learning to interpret pump messages help lead to an early diagnosis of heartware ventricular assist device thrombosis? ASAIO J 2012;58:629-32.
50. Jabbar AA, Yau R, Frazier OH, et al. Direct thrombolytic therapy for thrombosis of a centrifugal flow left ventricular assist device. ASAIO J 2013;59:530-2.
51. Dalen M, Sartipy U, Corbascio M, et al. HeartWare left ventricular assist device thrombosis in aspirin non-responder. Asian Cardiovasc Thorac Ann 2014;22:203-4.
52. Dimarakis I, Shaw S, Venkateswaran R. HeartWare left ventricular assist device thrombosis including outflow graft. J Thorac Cardiovasc Surg 2014; Feb. 8 [epub ahead of print]. doi:\10.1016/j.jtcvs.2014.01.049.
53. Gregoric ID, Bruckner BA, Jacob L, et al. Clinical experience with sternotomy versus subcostal approach for exchange of the HeartMate XVE to the HeartMate II ventricular assist device. Ann Thorac Surg 2008;85:1646-9.
54. Moazami N, Milano CA, John R, et al. Pump replacement for left ventricular assist device failure can be done safely and is associated with low mortality. Ann Thorac Surg 2013;95:500-5.
55. Ballew CC, Benton EM, Groves DS, et al. Comparing survival of HMII patients with elevated LDH: implications for medical and surgical management. J Heart Lung Transplant 2013;32:ns38.